BeOne Medicines AG Earnings
The next earnings date for BeOne Medicines AG has not yet been scheduled.
Analyst Estimates of BeOne Medicines AG Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
BeOne Medicines AG Earnings: Historical
| 11/05/2026 | Before Market | $3.64 | 55.56% |
| 08/05/2026 | Before Market | $2.05 | 46.43% |
| 05/06/2026 | Before Market | $1.96 | 141.98% |
| 02/26/2026 | --- | $0.58 | -63.75% |
| 11/06/2025 | Before Market | $1.09 | 26.74% |
| 08/06/2025 | Before Market | $0.84 | 223.08% |
| 05/07/2025 | Before Market | $0.01 | 101.35% |
| 02/27/2025 | --- | $-1.43 | -41.58% |
| 11/12/2024 | Before Market | $-1.15 | -3.60% |
| 08/07/2024 | Before Market | $-1.15 | 46.26% |
More About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
“BeOne Medicines AG Earnings” Can Refer to the BeOne Medicines AG Earnings Date
Some people say “BeOne Medicines AG earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my BeOne Medicines AG position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning BeOne Medicines AG Stock on the Earnings Date
If you own BeOne Medicines AG stock (ONC) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for BeOne Medicines AG might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading BeOne Medicines AG shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More BeOne Medicines AG Earnings
You can contact us any time if you would like to ask questions about BeOne Medicines AG earnings or anything else related to the stock market.